A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Latest Information Update: 07 Feb 2024
At a glance
- Drugs V 01 Livzon Mabpharm/Institute of Biophysics, Chinese Academy of Sciences (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Livzon Pharmaceuticals
- 18 Feb 2022 New trial record